Genmab halted patient enrollment in a Phase 1/2 trial of GEN1286, a cancer candidate acquired through its $1.8 billion purchase of ProfoundBio. The pause affects a study originally planned to enroll 260 patients and follows Genmab’s internal review after integration of the ProfoundBio portfolio. Genmab did not disclose whether the hold reflects safety, efficacy, or operational considerations, but the enrollment pause will delay readouts for a program that forms part of the company’s oncology pipeline expansion.